Which medications in the drug class Monoclonal antibody are used in the treatment of Thrombotic Thrombocytopenic Purpura (TTP)?

Updated: May 25, 2021
  • Author: Theodore Wun, MD, FACP; Chief Editor: Srikanth Nagalla, MD, MS, FACP  more...
  • Print

Monoclonal antibody

These agents have shown efficacy in the treatment of autoimmune disorders. Caplacizumab has been shown to reduce time to platelet count response and also to reduce aTTP-related death, recurrence, or major thromboembolic events. [5]

Caplacizumab (Cablivi, caplacizumab-yhdp)

Antibody fragment that targets the A1-domain of von Willebrand factor (vWF), and inhibits the interaction between vWF and platelets; thereby, reducing both vWF-mediated platelet adhesion and platelet consumption. It is indicated for aTTP in combination with plasma exchange and immunosuppressive therapy.

Rituximab (Rituxan)

Anti-CD20 chimeric monoclonal antibody initially approved for therapy of follicular lymphoma. Has been shown to have activity in several autoimmune disorders such as immune thrombocytopenia, systemic lupus erythematosus, autoimmune hemolytic anemia, and rheumatoid arthritis.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!